iBreeze BPAP

The iBreeze BPAP supports four therapy modes covering the full spectrum of non-invasive positive pressure applications:

CPAP: continuous single-pressure mode for straightforward obstructive sleep apnea. S (Spontaneous): delivers bilevel pressure triggered by the patient's own breathing, standard for OSA patients who need higher EPAP/IPAP differentials. S/T (Spontaneous/Timed): adds a backup respiratory rate for patients with central apnea events or variable respiratory drive. T (Timed): fully machine-controlled breathing rate for patients with minimal spontaneous effort.

This mode range means a single iBreeze BPAP unit covers clinical scenarios from mild OSA through complex chronic respiratory failure, reducing the number of device SKUs hospitals need to stock.

IPR reduces pressure during early exhalation: the moment when patients most commonly feel they're breathing against the machine. The iBreeze BPAP offers three IPR modes with adjustable intensity, letting clinicians fine-tune how aggressively the device drops pressure at the start of each breath out.

This isn't cosmetic. Exhalation discomfort is the single largest driver of PAP therapy dropout in the first 30 days. When patients feel they can't exhale naturally, they stop using the device. IPR addresses this directly by making the pressure transition feel more like natural breathing. For distributors selling into hospital sleep programs and DME channels, IPR is a tangible comfort differentiator that reduces return rates and improves 90-day adherence metrics, both of which affect reimbursement eligibility in managed care environments.

The iBreeze BPAP detects the onset of inspiration and switches from EPAP to IPAP in as little as 0.1 seconds, faster than most competing bilevel devices in the same price class. This speed directly affects how "natural" the device feels to the patient.

When there's a perceptible delay between the patient starting to inhale and the machine delivering pressure, it creates a fighting sensation called patient-ventilator asynchrony. This leads to air hunger, arousal from sleep, and ultimately device abandonment. The 0.1s trigger response keeps the iBreeze in lockstep with the patient's respiratory cycle, which is particularly important for S/T mode patients with irregular breathing patterns from central sleep apnea or neuromuscular conditions.

EVAPS (Essential Volume Assured Pressure Support) automatically adjusts inspiratory pressure to deliver a clinician-set target tidal volume, even as the patient's respiratory effort changes through sleep stages, positional shifts, or disease progression. This is a step beyond standard BiPAP, which only delivers fixed pressure differentials.

The clinical significance: patients with obesity hypoventilation syndrome, neuromuscular disease, or COPD overlap often have variable respiratory drive. Fixed bilevel pressure may underventilate during deep sleep and overventilate during lighter stages. EVAPS compensates dynamically, maintaining consistent alveolar ventilation throughout the night. For institutional buyers, this positions the iBreeze BPAP as a versatile device that covers both standard OSA bilevel therapy and more complex non-invasive ventilatory support cases on a single platform.

The iBreeze BPAP carries a standard manufacturer warranty covering defects in materials and workmanship. Warranty terms and duration are specified in each wholesale distribution agreement and may vary by market. SysMed handles all warranty claims directly: distributors don't need to coordinate with Resvent's factory in China.

For service parts (blower assemblies, circuit boards, pressure sensors, humidifier components), SysMed maintains Miami-based inventory for rapid fulfillment to LATAM markets. Replacement parts ship on the same logistics corridors as new devices, with typical lead times of 5 to 14 business days depending on destination. This matters because in-field device downtime directly affects your customer relationships: a hospital waiting 8 weeks for a part from Shenzhen is a hospital evaluating alternative suppliers.